Agile Therapeutics, Inc. Announces Three New U.S. Patents on Its Technology and the Brand Name Twirla(TM) for Its First Contraceptive Patch  
8/27/2012 9:21:45 AM

PRINCETON, NJ--(Marketwire - August 27, 2012) -

Agile Therapeutics today announced that the U.S. Patent and Trademark Office (USPTO) has issued three new patents with claims related to its contraceptive patch technology. The three new patents add to the company's existing portfolio and extend protection of the company's proprietary transdermal technology through at least 2028. Agile has also received a notice of allowance from the USPTO for the trademark Twirla™, and conditional acceptance from the FDA to use the proprietary name "Twirla" for its AG200-15 contraceptive patch, pending final agency review prior to NDA approval.

"We are thrilled that the USPTO issued these additional patents -- it underscores the proprietary nature of our transdermal technology and enhances the value of our intellectual property estate," said Al Altomari, President and CEO of Agile Therapeutics. "We are continuing to develop our patent portfolio in key markets around the world and the expansion in the U.S. is a great step forward."

The table below summarizes the issued U.S. patents currently held by Agile Therapeutics that are relevant to AG200-15:

 U.S. Patent
   Number            Date of Issue      Patent Expiration 
8,246,978           August 21, 2012     2028                
8,221,785           July 17, 2012       2021                
8,221,784           July 17, 2012       2021                
7,384,650           June 10, 2008       2021                
7,045,145           May 16, 2006        2021                

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch that recently completed Phase III clinical trials. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit

Karen Famighetti or Chantal Beaudry for Agile Therapeutics